DMAC Long Call Strategy

DMAC (DiaMedica Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

DMAC (DiaMedica Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $368.6M, a beta of 0.97 versus the broader market, a 52-week range of 5.14-10.4195, average daily share volume of 196K, a public-listing history dating back to 2012, approximately 35 full-time employees. These structural characteristics shape how DMAC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.97 places DMAC roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long call on DMAC?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

DMAC snapshot

As of August 14, 2026, spot at $6.73, ATM IV 114.10%, IV rank 23.57%, expected move 32.71%. The long call on DMAC below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long call structure on DMAC specifically: DMAC IV at 114.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a DMAC long call, with a market-implied 1-standard-deviation move of approximately 32.71% (roughly $2.20 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DMAC expiries trade a higher absolute premium for lower per-day decay. Position sizing on DMAC should anchor to the underlying notional of $6.73 per share and to the trader's directional view on DMAC stock.

DMAC long call setup

The DMAC long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DMAC at $6.73 on that close, the first option leg uses a $6.73 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DMAC chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DMAC shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$6.73N/A

DMAC long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

DMAC long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on DMAC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on DMAC

Long calls on DMAC express a bullish thesis with defined risk; traders use them ahead of DMAC catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

DMAC thesis for this long call

The market-implied 1-standard-deviation range for DMAC extends from approximately $4.53 on the downside to $8.93 on the upside. A DMAC long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current DMAC IV rank near 23.57% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DMAC at 114.10%. As a Healthcare name, DMAC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DMAC-specific events.

DMAC long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DMAC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DMAC alongside the broader basket even when DMAC-specific fundamentals are unchanged. Long-premium structures like a long call on DMAC are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current DMAC chain quotes before placing a trade.

Frequently asked questions

What is a long call on DMAC?
A long call on DMAC is the long call strategy applied to DMAC (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With DMAC stock at $6.73 on the most recent close, the strikes shown on this page are snapped to the nearest listed DMAC chain strike and the premiums come straight from that session's bid/ask midpoint.
How are DMAC long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the DMAC long call priced from the end-of-day chain at a 30-day expiry (ATM IV 114.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a DMAC long call?
The breakeven for the DMAC long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The DMAC market-implied 1-standard-deviation expected move in the same options snapshot is approximately 32.71%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on DMAC?
Long calls on DMAC express a bullish thesis with defined risk; traders use them ahead of DMAC catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current DMAC implied volatility affect this long call?
DMAC ATM IV is at 114.10% with IV rank near 23.57%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related DMAC analysis